Search

Displaying results 2231 - 2240 of 10000 in total
  1. Drug

    Doxecitine

    go.drugbank.com/drugs/DB02594
    ApprovedInvestigational

    It is an essential component of the deoxyribonucleotide pool required for DNA synthesis and repair. … Doxecitine is a synthetic form of the naturally occurring pyrimidine deoxyribonucleoside deoxycytidine.

  2. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  3. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin … Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations.

  4. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus. … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart

  5. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

  6. Drug

    Piperazine

    go.drugbank.com/drugs/DB00592
    ApprovedVet approvedWithdrawn

    Piperazine was first introduced as an anthelmintic in 1953. … First used as a solvent for uric acid, the use of piperazine as an anthelmintic agent was first introduced in 1953.

  7. Drug

    Pyrethrum extract

    go.drugbank.com/drugs/DB11087
    Approved

    The active compound is absorbed by the lice and destroys them by acting on their nervous systems but is thought to exert minimal effect on humans. … Pyrethrum extract is also used used to treat head, body, and pubic lice infections.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Nirsevimab

    go.drugbank.com/drugs/DB16258
    ApprovedInvestigational

    [A254691] This is due to a modification in the Fc region of nirsevimab that grants it a longer half-time compared to typical monoclonal antibodies. … [L44146] Nirsevimab was also approved by Health Canada on April 19, 2023 and by the FDA in July 17, 2023 for the same indication.[L46392,L47461]

  9. Drug

    Choline C 11

    go.drugbank.com/drugs/DB09277
    Approved

    [A32041] It was developed by MCPRF and FDA first approved in September 2012. … Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes.

  10. Drug

    Brepocitinib

    go.drugbank.com/drugs/DB15003
    ApprovedInvestigational

    Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults. … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.